Stock Track | CANSINOBIO Soars 5% as Q3 Net Profit Skyrockets 842%, Driven by Strong MenHibrix Sales

Stock Track

Oct 31

CANSINOBIO (06185) experienced a significant surge in its stock price, soaring 5.01% during intraday trading on Friday. The sharp increase comes on the heels of the company's impressive third-quarter financial results, which showcased substantial growth in both revenue and profitability.

According to the company's latest financial report, CANSINOBIO's Q3 revenue reached RMB310 million, marking a 17.67% year-over-year increase. More notably, the net profit attributable to shareholders skyrocketed by an astounding 842.01% compared to the same period last year, reaching RMB27.93 million. This remarkable performance extends beyond the quarter, with the first nine months of the year showing a 22.13% year-over-year revenue increase to RMB693 million, and a return to profitability with a net profit of RMB14.44 million.

The driving force behind CANSINOBIO's stellar performance is the strong market uptake of its core product, MenHibrix. As the only quadrivalent meningococcal conjugate vaccine available in China's meningitis vaccine market, MenHibrix's innovative advantages have significantly boosted the company's market share. The product's success has been instrumental in fueling the company's revenue growth and profitability, leading to increased investor confidence and the subsequent stock price surge.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1191565626"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1191565626\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1191565626?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 13:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191565626","market":"nz","top_or_hot":-1,"title":"Stock Track | CANSINOBIO Soars 5% as Q3 Net Profit Skyrockets 842%, Driven by Strong MenHibrix Sales","media":"Stock Track","content":"<p>CANSINOBIO (06185) experienced a significant surge in its stock price, soaring 5.01% during intraday trading on Friday. The sharp increase comes on the heels of the company's impressive third-quarter financial results, which showcased substantial growth in both revenue and profitability.</p>\n\n<p>According to the company's latest financial report, CANSINOBIO's Q3 revenue reached RMB310 million, marking a 17.67% year-over-year increase. More notably, the net profit attributable to shareholders skyrocketed by an astounding 842.01% compared to the same period last year, reaching RMB27.93 million. This remarkable performance extends beyond the quarter, with the first nine months of the year showing a 22.13% year-over-year revenue increase to RMB693 million, and a return to profitability with a net profit of RMB14.44 million.</p>\n\n<p>The driving force behind CANSINOBIO's stellar performance is the strong market uptake of its core product, MenHibrix. As the only quadrivalent meningococcal conjugate vaccine available in China's meningitis vaccine market, MenHibrix's innovative advantages have significantly boosted the company's market share. The product's success has been instrumental in fueling the company's revenue growth and profitability, leading to increased investor confidence and the subsequent stock price surge.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CANSINOBIO Soars 5% as Q3 Net Profit Skyrockets 842%, Driven by Strong MenHibrix Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CANSINOBIO Soars 5% as Q3 Net Profit Skyrockets 842%, Driven by Strong MenHibrix Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-31 13:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CANSINOBIO (06185) experienced a significant surge in its stock price, soaring 5.01% during intraday trading on Friday. The sharp increase comes on the heels of the company's impressive third-quarter financial results, which showcased substantial growth in both revenue and profitability.</p>\n\n<p>According to the company's latest financial report, CANSINOBIO's Q3 revenue reached RMB310 million, marking a 17.67% year-over-year increase. More notably, the net profit attributable to shareholders skyrocketed by an astounding 842.01% compared to the same period last year, reaching RMB27.93 million. This remarkable performance extends beyond the quarter, with the first nine months of the year showing a 22.13% year-over-year revenue increase to RMB693 million, and a return to profitability with a net profit of RMB14.44 million.</p>\n\n<p>The driving force behind CANSINOBIO's stellar performance is the strong market uptake of its core product, MenHibrix. As the only quadrivalent meningococcal conjugate vaccine available in China's meningitis vaccine market, MenHibrix's innovative advantages have significantly boosted the company's market share. The product's success has been instrumental in fueling the company's revenue growth and profitability, leading to increased investor confidence and the subsequent stock price surge.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"","article_id":"1191565626","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191565626","pubTimestamp":1761887217,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CANSINOBIO (06185) experienced a significant surge in its stock price, soaring 5.01% during intraday trading on Friday. The sharp increase comes on the heels of the company's impressive third-quarter...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06185":"康希诺生物"},"translate_title":"个股赛道|康希诺生物大涨5%Q3净利润暴涨842%受MenHibrix销售强劲推动","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"CANSINOBIO (06185) experienced a significant surge in its stock price, soaring 5.01% during intraday trading on Friday. The sharp increase comes on the heels of the company's impressive third-quarter financial results, which showcased substantial growth in both revenue and profitability.\nAccording to the company's latest financial report, CANSINOBIO's Q3 revenue reached RMB310 million, marking a 17.67% year-over-year increase. More notably, the net profit attributable to shareholders skyrocketed by an astounding 842.01% compared to the same period last year, reaching RMB27.93 million. This remarkable performance extends beyond the quarter, with the first nine months of the year showing a 22.13% year-over-year revenue increase to RMB693 million, and a return to profitability with a net profit of RMB14.44 million.\nThe driving force behind CANSINOBIO's stellar performance is the strong market uptake of its core product, MenHibrix. As the only quadrivalent meningococcal conjugate vaccine available in China's meningitis vaccine market, MenHibrix's innovative advantages have significantly boosted the company's market share. The product's success has been instrumental in fueling the company's revenue growth and profitability, leading to increased investor confidence and the subsequent stock price surge.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}